Markets:

Overview

News

Currencies

International

Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

8.480 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Intellia Therapeutics Inc (NASDAQ:NTLA) Q2 2025 Earnings: Revenue Surpasses Estimates, Losses Narrower Than Expected ↗

August 07, 2025

Intellia Therapeutics (NTLA) reported Q2 2025 revenue of $14.25M, beating estimates, with a narrower loss of $0.99 per share. Stock rose 2% pre-market amid strong clinical progress in CRISPR...

Via Chartmill

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

July 31, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? ↗

July 30, 2025

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

Via Benzinga

Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews ↗

May 29, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

A Glimpse of Intellia Therapeutics's Earnings Potential ↗

May 07, 2025

Via Benzinga

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook ↗

July 15, 2025

Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO.

Via MarketBeat

Topics Economy Stocks

FDA Approves KalVista's Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease ↗

July 07, 2025

KalVista's Ekterly, backed by strong trial data, receives FDA approval as the first oral therapy for acute hereditary angioedema attacks in the US.

Via Benzinga

FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering ↗

June 20, 2025

FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research

Via Benzinga

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗

June 18, 2025

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Via Benzinga

Jabil Posts Upbeat Earnings, Joins Verve Therapeutics, John Wiley & Sons And Other Big Stocks Moving Higher On Tuesday ↗

June 17, 2025

Via Benzinga

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover ↗

June 17, 2025

The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.

Via Investor's Business Daily

Assessing Intellia Therapeutics: Insights From 9 Financial Analysts ↗

June 16, 2025

Via Benzinga

Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration ↗

May 30, 2025

Ark Invest made significant trades in TSLA, TXG, NTLA, DDD, and ADPT. Purchase of TXG and NTLA from ARKG and ARKK funds, and sale of TSLA, DDD, and ADPT from various funds.

Via Benzinga

Topics Government

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 29, 2025

Via Benzinga

Keep an eye on the top gainers and losers in Thursday's session. ↗

May 29, 2025

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip ↗

May 29, 2025

The patient’s elevated levels of liver enzymes appear to be resolving without hospitalization or medical intervention, the company said.

Via Stocktwits

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course ↗

May 29, 2025

Intellia reports a grade 4 liver enzyme elevation in a Nex-Z trial patient; no hospitalization is required, and enrollment remains on track across programs.

Via Benzinga

The market is filled with gapping stocks in Thursday's session. ↗

May 29, 2025

Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

HP Posts Downbeat Earnings, Joins SentinelOne, Best Buy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

May 29, 2025

Via Benzinga

What's going on in today's pre-market session ↗

May 29, 2025

Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 29, 2025

Via Benzinga

Why Nvidia Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket ↗

May 29, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 28, 2025

Via Benzinga

Analysts Think These Stocks Could More Than Double in Value

May 23, 2025

Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.

Via MarketBeat

Topics World Trade

INTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

May 22, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Forecasting The Future: 11 Analyst Projections For Intellia Therapeutics ↗

May 12, 2025

Via Benzinga

Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday ↗

May 12, 2025

Via Benzinga

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

April 30, 2025

Via The Motley Fool

Topics Artificial Intelligence World Trade

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

All News about Intellia Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today